# Ysios Capital
Ysios Capital is a Spanish venture capital firm specializing in life sciences, founded in 2008 and headquartered in Barcelona and [San Sebastián](https://www.edgepedia.org/san-sebastian), which manages over €400 million across three venture capital funds and advises a listed biotech fund.[1](https://ysioscapital.com/2026/03/27/ysios-capital-launches-inceptionbio-a-e100m-fund-to-drive-biotech-company-creation/) Independent reporting describes it as Spain's largest life sciences venture capital manager.[2](https://thenextweb.com/news/ysios-capital-inceptionbio-100m-fund) In March 2026 the firm launched InceptionBio, a €100 million fund dedicated to creating new biotech companies, and it remains actively investing as of that date.
| Key facts | |
|---|---|
| Founded | 2008[1](https://ysioscapital.com/2026/03/27/ysios-capital-launches-inceptionbio-a-e100m-fund-to-drive-biotech-company-creation/) |
| Headquarters | Barcelona and San Sebastián, Spain[1](https://ysioscapital.com/2026/03/27/ysios-capital-launches-inceptionbio-a-e100m-fund-to-drive-biotech-company-creation/) |
| Founders | Joël Jean-Mairet (former CEO of GLYCART Biotechnology AG) and Julia Salaverría[3](https://ysioscapital.com/wp-content/uploads/2021/06/Press-Release-Ysios-First-Closing-080915.pdf) |
| Sector | Life sciences[1](https://ysioscapital.com/2026/03/27/ysios-capital-launches-inceptionbio-a-e100m-fund-to-drive-biotech-company-creation/) |
| Assets under management | Over €400 million across three VC funds, plus advisory to Telescope Biotech Fund[1](https://ysioscapital.com/2026/03/27/ysios-capital-launches-inceptionbio-a-e100m-fund-to-drive-biotech-company-creation/) |
| Headline exits | Tigenix to Takeda (~€450M), STAT-Diagnostica to Qiagen (€172M), Sanifit to Vifor Pharma (€375M)[1](https://ysioscapital.com/2026/03/27/ysios-capital-launches-inceptionbio-a-e100m-fund-to-drive-biotech-company-creation/) |
| Latest fund | InceptionBio, €100M target, first closing March 2026[1](https://ysioscapital.com/2026/03/27/ysios-capital-launches-inceptionbio-a-e100m-fund-to-drive-biotech-company-creation/) |
| Status | Active (March 2026)[1](https://ysioscapital.com/2026/03/27/ysios-capital-launches-inceptionbio-a-e100m-fund-to-drive-biotech-company-creation/) |
## History and people
The Ysios Capital Partners team was created by its partners, among them Joël Jean-Mairet, former CEO of the Swiss biotechnology company GLYCART Biotechnology AG, and Julia Salaverría.[3](https://ysioscapital.com/wp-content/uploads/2021/06/Press-Release-Ysios-First-Closing-080915.pdf) In 2015 the firm proceeded to the first close of what its press release called the largest Spanish biotech fund, at €67 million.[3](https://ysioscapital.com/wp-content/uploads/2021/06/Press-Release-Ysios-First-Closing-080915.pdf)
Leadership changed in March 2026 alongside the launch of InceptionBio. Joan Perelló became Managing Partner of the new vehicle, with Arturo Urrios as Partner.[1](https://ysioscapital.com/2026/03/27/ysios-capital-launches-inceptionbio-a-e100m-fund-to-drive-biotech-company-creation/) Joël Jean-Mairet remains Managing Partner of the firm's main funds.[2](https://thenextweb.com/news/ysios-capital-inceptionbio-100m-fund)
## Investment strategy
Ysios invests in life sciences companies, and its InceptionBio vehicle has a strong focus on Spain.[1](https://ysioscapital.com/2026/03/27/ysios-capital-launches-inceptionbio-a-e100m-fund-to-drive-biotech-company-creation/) Its later-stage flagship, BioFund III, backs development-stage companies and is described in 2026 reporting as a €216 million vehicle launched in 2020.[2](https://thenextweb.com/news/ysios-capital-inceptionbio-100m-fund)
**InceptionBio** extends the strategy to the earliest stage. It is a fund, not a platform company, dedicated exclusively to biotech company creation: it works through technology transfer with universities, hospitals, and research centers to build companies at pre-seed and seed stage, an approach that complements BioFund III.[2](https://thenextweb.com/news/ysios-capital-inceptionbio-100m-fund) The firm says the launch marks the first time it has structured a €100 million vehicle around the company-creation stage.[2](https://thenextweb.com/news/ysios-capital-inceptionbio-100m-fund)
Separately from its funds, Ysios acts as investment advisor to Telescope Biotech Fund, a listed biotech fund managed by Andbank Wealth Management; reporting states it returned 52.5% net in its first year.[1](https://ysioscapital.com/2026/03/27/ysios-capital-launches-inceptionbio-a-e100m-fund-to-drive-biotech-company-creation/) • [2](https://thenextweb.com/news/ysios-capital-inceptionbio-100m-fund)
## Funds, by the numbers
As of March 2026 the firm manages over €400 million through three venture capital funds.[1](https://ysioscapital.com/2026/03/27/ysios-capital-launches-inceptionbio-a-e100m-fund-to-drive-biotech-company-creation/) The first fund dates to the 2008 founding; the 2015 first close of its second-generation vehicle reached €67 million.[3](https://ysioscapital.com/wp-content/uploads/2021/06/Press-Release-Ysios-First-Closing-080915.pdf) An unverified industry directory lists BioFund I at €65M (2008 vintage), BioFund II Innvierte at €126M (2016 vintage), and BioFund III at €216M (2020 vintage).[4](https://www.gp-intel.com/gp/ysios-capital-partners)
InceptionBio has a target size of €100 million and completed a first closing in March 2026 with participation from the Centro para el Desarrollo Tecnológico y la Innovación (CDTI) through its SICC Innvierte program; the firm aims for it to support the creation of at least three new biotech companies in 2026.[1](https://ysioscapital.com/2026/03/27/ysios-capital-launches-inceptionbio-a-e100m-fund-to-drive-biotech-company-creation/) The first closing is not the final one, and no final size or date has been reported.
## Portfolio and exits
Ysios has invested in more than 40 biotech companies and completed six NASDAQ exits and ten M&A transactions, according to the firm.[1](https://ysioscapital.com/2026/03/27/ysios-capital-launches-inceptionbio-a-e100m-fund-to-drive-biotech-company-creation/) Its best-known trade sales are the acquisition of Tigenix by Takeda for approximately €450 million, the sale of STAT-Diagnostica to Qiagen for €172 million, and the acquisition of [Sanifit](https://www.edgepedia.org/sanifit) by Vifor Pharma for €375 million; the exit values are firm-reported figures.[1](https://ysioscapital.com/2026/03/27/ysios-capital-launches-inceptionbio-a-e100m-fund-to-drive-biotech-company-creation/) Independent reporting confirms STAT-Diagnostica among its portfolio, alongside [SpliceBio](https://www.edgepedia.org/splicebio), Ona Therapeutics, and [Minoryx Therapeutics](https://www.edgepedia.org/minoryx-therapeutics).[2](https://thenextweb.com/news/ysios-capital-inceptionbio-100m-fund) • [5](https://en.ara.cat/economy/ysios-capital-launches-100m-fund-to-boost-the-creation-of-biotech-companies_1_5691420.html)
An unverified directory additionally lists LAVA Therapeutics (Netherlands, 2021 IPO), Mineralys Therapeutics (US, 2023 IPO), and Memo Therapeutics (Switzerland, 2026 trade sale) among its exits.[4](https://www.gp-intel.com/gp/ysios-capital-partners)
## References
1. Ysios Capital press release: "Ysios Capital launches InceptionBio, a €100M fund to drive biotech company creation" (March 27, 2026). https://ysioscapital.com/2026/03/27/ysios-capital-launches-inceptionbio-a-e100m-fund-to-drive-biotech-company-creation/
2. TNW: "Ysios Capital launches €100M fund to build biotech companies from Spanish science". https://thenextweb.com/news/ysios-capital-inceptionbio-100m-fund
3. Ysios Capital press release (2015): "Ysios Capital Partners proceeds to first close of the largest Spanish biotech fund at 67 million Euros". https://ysioscapital.com/wp-content/uploads/2021/06/Press-Release-Ysios-First-Closing-080915.pdf
4. GP Intel directory profile: "Ysios Capital Partners" (unverified aggregator data). https://www.gp-intel.com/gp/ysios-capital-partners
5. Ara: "Ysios Capital launches a €100M fund to boost the creation of biotech companies". https://en.ara.cat/economy/ysios-capital-launches-100m-fund-to-boost-the-creation-of-biotech-companies_1_5691420.html
---
*Topic: Encyclopedia › Society and history › Economics and business › Finance › Venture capital and private equity › Venture capital firms of Europe, the Middle East, and Africa › Venture capital firms of Western Europe*
*Initially written Sep 17, 2026 · Edited: Oct 11, 2026; Oct 15, 2026*
*Copyright 2026 EdgeChat AI, a subsidiary of Biostate AI.*
License: Edgepedia Community License 1.0, https://www.edgepedia.org/edgepedia/license